

[For immediate release]

**Bloomage BioTechnology Corporation Limited**
華熙生物科技股份有限公司**BLOOMAGE BIOTEC ANNOUNCES ALLOTMENT RESULTS**

* * * *

PUBLIC OFFER RECORDED AROUND 4.1 TIMES SUBSCRIBED

(Hong Kong, 30 September 2008) – Bloomage BioTechnology Corporation Limited (“Bloomage BioTec”, stock code: 00963), a hyaluronic acid (HA) manufacturer in China, today announced that the results of its Public Offer of 7,800,000 Shares was approximately 4.1 times subscribed, while 70,200,000 Placing Shares were moderately oversubscribed.

Based on the offer price of HK\$1.00 per share and excluding underwriting commission and other estimated share offer expenses, Bloomage BioTec’s net proceeds are estimated at approximately HK\$60 million. The proceeds will be used mainly for constructing new production lines for eye drop and injection grade HA products, as well as finished injection grade HA products under the medical device category, enhancing R&D capabilities, and promotion and expansion of the Group’s distribution network. The remaining balance will be used as general working capital of the Group.

Ms. Zhao Yan, Chairman and Executive Director of Bloomage BioTec, said, “I am very grateful to the support of the investors and the public. This represents their confidence in the prospects of the biotechnology industry and Bloomage BioTec. The sales of HA for pharmaceutical uses had increased at a CAGR of approximately 36.5% between 1998 and 2007. Being the only HA manufacturer in China that obtains the drug manufacturing permit for the production of HA to be used as pharmaceutical excipients, Bloomage BioTec will highly benefit from the market’s strong growth. Looking ahead, we will put best effort to become the top HA producer in both domestic and international markets.”

Hantec Capital Limited is the Sponsor of the listing and Oriental Patron Asia Limited is the Sole Bookrunner and Lead Manager.

Shares in Bloomage BioTec are expected to commence dealing on the Main Board of The Hong Kong Stock Exchange Limited on 3 October 2008 (Friday) under the stock code of 00963.HK.

~ End ~

About Bloomage BioTechnology Corporation Limited (stock code: 00963.HK)

Bloomage BioTec produces four different grades of hyaluronic acid (“HA”) products of different specifications in China, namely injection, eye drop, cosmetics and food grades. Being the only HA manufacturer in China that obtains the drug manufacturing permit for the production of HA to be used as pharmaceutical excipients, it has over 650 domestic and international customers. HA is a natural hydration factor widely used in pharmaceutical, cosmetic and healthcare products. Riding on its leading R&D capabilities, the Group continues to expand its product portfolio by launching new products, and to increase the yield rate for the production of reliable and high quality HA products.

FOR ENQUIRIES:

Strategic Financial Relations (China) Limited

Ms. Serine Li	(852) 2864 4811	serine.li@sprg.com.hk
Ms. Katie Kung	(852) 2864 4830	katie.kung@sprg.com.hk
Ms. Janice Au	(852) 2864 4874	janice.au@sprg.com.hk
Ms. Cathy Zhang	(852) 2114 4963	cathy.zhang@sprg.com.hk